Council of Governors
Total Page:16
File Type:pdf, Size:1020Kb
Council of Governors Board Room, The Royal Marsden Hospital, London Wednesday 14th May 2014, 11am - 1pm followed by lunch 1 Welcome from the Chairman 2 Minutes of the meeting held on 5th March 2014 (enclosed) (Chairman) 3 Presentation: ‘Sutton for Life’ (enclosed) (Director of Projects and Estates) 4 Governor update 4.1. Members Event held on 28th April 2014 (enclosed) (Governor Maggie Harkness) 4.2. FTGA Spring Development Day held on 26th March 2014 (enclosed) (Governor Peter Lewins) 4.3. Deloitte: ‘Evolving governance requirements’ held on 31st March 2014 (enclosed) (Governor Duncan Campbell) 5 Corporate Governance 5.1. NED Appointment – for decision (enclosed) 5.2. Governor elections – for information (enclosed) (Chairman) 5.3. Progress report on Governor Working Groups – for information (enclosed) 5.4. Evaluation of the Council– for decision (enclosed) (Assistant Director of Organisation Development) 6 Update on the Royal Brompton Estate 6.1. Progress report on the Royal Brompton Estate (enclosed) (Chief Executive / Director of Projects and Estates) 6.2. Communications Strategy (enclosed) (Director of Marketing and Communications) 7 Finance Report 7.1. Operational Plan 2014-16 (enclosed) 7.2. Financial Report 2013/14 (enclosed) (Director of Finance) 8 Quality and Performance 8.1. Key Performance Indicators Q4 (enclosed) (Director of Performance and Strategy Implementation) 8.2. Quality Accounts for March 2014 (enclosed) 8.3. Annual Quality Accounts for 2013 / 14 (enclosed) (Chief Nurse) 8.4. Update on Outpatient Waiting Times (Chief Operating Officer) (enclosed) 9 Equality Strategy (Assistant Director of Organisation Development) (enclosed) 10 Audit and Finance Committee 10.1. Annual Report for 2013 / 14 (enclosed) 10.2. Highlight Report from meeting held on 9th April 2014 (enclosed) 10.3. Tendering of the external auditor (enclosed) (Ian Farmer, Chair of Audit and Finance Committee) 11 Any Other Business Date of next meeting: Tuesday 16th September 2014, 11 am - 1 pm Board Room, Chelsea Page 2 of 2 Council of Governors Board Room, The Royal Marsden Hospital, Chelsea Wednesday 5th March 2014 11:00am – 13:00pm Minutes Present:- R. Ian Molson (Chairman) Governors as per attached attendance list In attendance Cally Palmer (Chief Executive) Nancy Hallett (Non-Executive Director) Dr Liz Bishop (Chief Operating Officer) Alan Goldsman (Director of Finance) Dr Shelley Dolan (Chief Nurse) Professor Martin Gore (Medical Director) Nicky Browne (Director of Performance & Strategy Implementation) Maggie Gairdner (Divisional Director of Sutton and Merton Community Services) Syma Dawson (Head of Corporate Governance) Samantha Greenhouse (Assistant Director of Organisational Development) MEETING BUSINESS 1 Apologies Vikki Orvice (Governor) Cllr Stephen Alambritis (Governor) Dr Claire Dearden (Governor) Bernadette Knight (Governor) Robert Shearer (Governor) Sarah Clarke (Divisional Director of Cancer Services) 2 Minutes of meeting held on the 3rd December 2013 The minutes of meeting held on the 3rd December 2013 were approved subject to minor amendments. 3 Corporate Governance 3.1. Senior Independent Director The Chairman noted the Board’s decision to appoint Nancy Hallett, Non-Executive Director as the Senior Independent Director. 3.2. Proposed Framework for Governor Engagement and Involvement The Assistant Director of Organisational Development presented the proposed framework to the Council and highlighted the following key matters: • Ensuring the safety, quality and effectiveness of patient care through the proposed Patient and Carer Quality Group • Refreshing of the Membership and Communications group to help recruit new members and further engage with existing members • Information which is accessible to the public, including Board meetings Fiona Stewart requested clarification in terms of the impact of the proposed framework on the role of PCAG. In response, the Chief Nurse recognised the important work of PCAG and explained that she was due to attend the next PCAG meeting to discuss the proposal, which will still involve the work of PCAG and aim to improve current arrangements for the benefit of the Trust. Page 1 of 7 In response to a query raised by Duncan Campbell, the Chief Nurse explained that the Trust wanted to avoid having too many groups and both she and the Chair of PCAG are considering what can be done altogether. The Chairman asked the Council to reflect on the proposal over the coming weeks and to send feedback to the Head of Corporate Governance. It was agreed that an update will be brought back to the next Council of Governor meeting. 3.3. NED Appointments The Chairman provided an update to the Council of Governors with regard to the recruitment of two NED’s to replace departing NEDs Greg Andrews, Chair of the Audit and Finance Committee and Colin Clark. • Chair of the Audit and Finance Committee and Non-Executive Director The Chairman informed the Council that a candidate, Ian Farmer, has been successfully identified for the position of Chair of the Audit and Finance Committee. The Chairman gave an overview of the selection and recruitment process which had been followed and how those who have met the candidate in question fully endorse the recommendation of the appointment. Duncan Campbell and Fiona Stewart added how impressed they were by the candidate’s commitment and enthusiasm for the role and Trust. The Chairman confirmed that although the candidate may occupy another role elsewhere in future, the candidate would make the necessary time available for the role. The Council approved the appointment of Ian Farmer to Non-Executive Director position and Chair of the Audit and Finance Committee for a period of three years, commencing 1st April 2014. • Non-Executive Director Sir John Craven The Chairman noted that the current term of office for NED Sir John Craven was due to expire and therefore, the Council is required function with regard to his reappointment. It was noted how Sir John has expressed a keen interest in remaining a member of the Board and has requested reappointment on an annual basis should the Council approve. Fiona Stewart queried whether the Trust ought to plan in terms of succession planning. In response, the Chief Executive confirmed that the Trust will plan accordingly and seek a replacement when the need arises. The Council approved the reappointment of Sir John Craven which will commence on the 1st April 2014 and is subject to annual review by the Council. 3.4. Feedback from Governors Awareness Session Carol Joseph reported that an Awareness Session was held for Governors, which was delivered by Ray Tarling from DAC Beachcroft. A key focus of this session was how Governors can add value to the organisation, particularly in accordance with their new responsibilities under the Health and Social Care Act 2012. Carol Joseph queried the Board’s approach in terms of having Board Seminars. In response, the Chief Executive explained that the Board requires the ability to prepare and discuss strategic issues in confidence before it is presented to the Council. The Board Seminar’s will therefore provide such a forum and ensure the Board can effectively function in such a way. Carol Joseph requested a financial seminar to help the Governors understanding in this area, to which the Director of Finance agreed to facilitate. 4 Presentation: Opening of West Wing Clinical Research Centre The Chief Executive introduced Rachel Turner, Clinical Research Business Manager and Angela Little, Matron, to present on the new West Wing Clinical Research Centre in Sutton. Page 2 of 7 Rachel Turner explained Clinical Research at The Royal Marsden, including its background, context and how the West Wing Clinical Research Centre will have a positive effect in improving patient care. The Charity’s contribution and support to the Centre was emphasised and how the West Wing Clinical Research Centre is an MDU in a research setting. The layout of the facilities was illustrated via imaging and a virtual tour alongside a discussion about the selection of clinical trials and review of clinical research protocols. Kate Law queried whether there had been any contention with the opening of the Centre with other partners. In response, Rachel Turner explained how the site appeases both academic and commercially sponsored partners given its portfolio. The Chairman queried the amount of prospective trials which have been declined because they have not complied with the requirements of a protocol. The Medical Director assured the Chairman and Council that this is a rare occasion as some can be very specific and designed with a particular hospital in mind. The Chief Operating Officer highlighted the following: 1) A trial set-up meeting has been established and is Chaired by the Associate Director of Clinical Research 2) A structured process of leadership has also been established so that each tumour group has a research lead The Chief Operating Officer invited Governors to have tours of the Centre should they wish and recognised the excellent contribution of Rachel Turner, Angela Little and other staff in the opening of the Centre. In response to a query raised by Ann Curtis as to whether the Trust was sharing outcomes with other hospitals, the Medical Director added that hospitals generally share lessons learnt and in this case, the same approach will be taken. Duncan Campbell asked whether there is any contention between research protocol and patient care. The Medical Director informed the Council that a basic rule of clinical research is that a patient’s needs always take precedence over the research protocol. The Chairman recognised the growing totality of research within The Royal Marsden and the Board’s responsibility to ensure the Trust operates the highest possible standards which are embedded in the organisation. 5 Presentation: Patient Public Involvement in Research The Chief Executive welcomed the BRC Assistant Director, Rowena Sharpe to present on Patient Public Involvement (PPI) in Research, with reference to PPI for the BRC in the enclosed paper. Rowena Sharpe explained the background of the BRC to the Council and how this benefits The Royal Marsden as the only established Cancer BRC.